Quick Answer
NYMOX PHARMACEUTICAL CORP reported R&D Expense of $3.28 million for fiscal year 2024.
NYMOX PHARMACEUTICAL CORP R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $3.28M | -17.9% |
| 2023 | $3.99M | +5.9% |
| 2022 | $3.77M | -43.3% |
| 2021 | $6.66M | -18.0% |
| 2020 | $8.12M | +10.1% |
| 2019 | $7.38M | +10.5% |
| 2018 | $6.68M | -15.2% |
| 2017 | $7.87M | +15.8% |
| 2016 | $6.80M | -21.4% |
| 2015 | $8.65M | — |
- NYMOX PHARMACEUTICAL CORP showed a decrease of -17.9% in R&D Expense compared to the prior fiscal year.
- Over the 2015–2024 period, NYMOX PHARMACEUTICAL CORP’s r&d expense has declined by 62.1% (from $8.65 million to $3.28 million).
- The most recent figure is from NYMOX PHARMACEUTICAL CORP’s fiscal year 2024 report (Form 20-F), filed with the SEC on June 3, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: